HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bo-Eric Persson Selected Research

Leuprolide (Lupron)

12/2014Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
7/2012The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
9/2011A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
12/2010Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
7/2010Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
5/2010Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
12/2008The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bo-Eric Persson Research Topics

Disease

20Prostatic Neoplasms (Prostate Cancer)
04/2016 - 08/2002
3Injection Site Reaction
06/2015 - 12/2008
2Neoplasm Metastasis (Metastasis)
04/2016 - 07/2010
2Urinary Tract Infections (Urinary Tract Infection)
01/2013 - 12/2008
2Neoplasms (Cancer)
07/2012 - 01/2009
2Hypersensitivity (Allergy)
06/2011 - 01/2009
1Acute Kidney Injury (Acute Renal Failure)
08/2014
1Lower Urinary Tract Symptoms
01/2013
1Cystitis
01/2013
1Spinal Cord Compression
06/2011
1Myocardial Ischemia (Ischemic Heart Diseases)
12/2010
1Hypogonadism (Hypergonadotropic Hypogonadism)
12/2010
1Heart Diseases (Heart Disease)
12/2010
1Adenocarcinoma
12/2008
1Gynecomastia
08/2002
1Disease Progression
08/2002
1Mastodynia
08/2002

Drug/Important Bio-Agent (IBA)

15acetyl- 2- naphthylalanyl- 3- chlorophenylalanyl- 1- oxohexadecyl- seryl- 4- aminophenylalanyl(hydroorotyl)- 4- aminophenylalanyl(carbamoyl)- leucyl- ILys- prolyl- alaninamideFDA Link
04/2016 - 10/2008
11Gonadotropin-Releasing Hormone (GnRH)FDA Link
04/2016 - 03/2005
8AndrogensIBA
04/2016 - 12/2008
7Hormones (Hormone)IBA
04/2016 - 03/2005
7Leuprolide (Lupron)FDA LinkGeneric
12/2014 - 12/2008
6Testosterone (Sustanon)FDA Link
07/2012 - 10/2008
6Prostate-Specific Antigen (Semenogelase)IBA
07/2012 - 10/2008
4Androgen Antagonists (Antiandrogens)IBA
04/2016 - 06/2011
3LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
12/2009 - 10/2008
2Goserelin (Zoladex)FDA Link
12/2014 - 01/2013
2GonadotropinsIBA
11/2008 - 10/2008
1abarelix (Plenaxis)FDA Link
06/2011
1Pharmaceutical PreparationsIBA
12/2010
1Alkaline PhosphataseIBA
07/2010
1bicalutamide (Casodex)FDA LinkGeneric
08/2002

Therapy/Procedure

11Therapeutics
04/2016 - 08/2002
1Aftercare (After-Treatment)
06/2015
1Castration
01/2009
1Injections
11/2008
1Radiotherapy
08/2002
1Prostatectomy (Retropubic Prostatectomy)
08/2002